[1]Patent:WO2014/1973,2014,A1,.Locationinpatent:Page/Pagecolumn56;57;58
[2]JournalofMedicinalChemistry,2015,vol.58,#1,p.419-432
[1]Patent:WO2014/1973,2014,A1,
[2]JournalofMedicinalChemistry,2015,vol.58,#1,p.419-432
[1]Patent:WO2014/1973,2014,A1,
[2]JournalofMedicinalChemistry,2015,vol.58,#1,p.419-432
[1]Patent:WO2014/1973,2014,A1,
[1]Patent:WO2014/1973,2014,A1,
Title: Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.
Journal: Journal of medicinal chemistry 20150108
Title: Henderson JL, et al. Discovery and preclinical profiling of 3--(morpholin-4-yl)-7H-pyrrolo,3-dpyrimidin-5-ylbenzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem. 2015 Jan 8;58(1):419-32.
Title: Mendivil-Perez M, et al. Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease. Neurochem Res. 2016 Oct;41(10):2675-2692.
Title: Daher JP, et al. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration. J Biol Chem. 2015 Aug 7;290(32):19433-44.
